Ionis Pharmaceuticals, Inc.: net finite-lived intangible assets

What this measure means

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Exact concept: us-gaap:FiniteLivedIntangibleAssetsNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2016-12-31 to 2021-12-31. The SEC response was captured on 2026-09-19.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Ionis Pharmaceuticals, Inc.: total assets
• Ionis Pharmaceuticals, Inc.: total liabilities
• Ionis Pharmaceuticals, Inc.: stockholders equity
• Ionis Pharmaceuticals, Inc.: cash and cash equivalents
• Ionis Pharmaceuticals, Inc.: net income or loss
• Ionis Pharmaceuticals, Inc.: operating cash flow
• Ionis Pharmaceuticals, Inc.: capital expenditure payments
• Ionis Pharmaceuticals, Inc.: revenue
• Ionis Pharmaceuticals, Inc.: contract revenue excluding tax
• Ionis Pharmaceuticals, Inc.: financing cash flow
• Ionis Pharmaceuticals, Inc.: investing cash flow
• Ionis Pharmaceuticals, Inc.: retained earnings or deficit
• Ionis Pharmaceuticals, Inc.: basic weighted-average shares
• Ionis Pharmaceuticals, Inc.: diluted weighted-average shares
• Ionis Pharmaceuticals, Inc.: basic earnings per share
• Ionis Pharmaceuticals, Inc.: diluted earnings per share
• Ionis Pharmaceuticals, Inc.: income tax expense or benefit
• Ionis Pharmaceuticals, Inc.: net property, plant and equipment
• Ionis Pharmaceuticals, Inc.: share-based compensation expense
• Ionis Pharmaceuticals, Inc.: operating income or loss
• Ionis Pharmaceuticals, Inc.: current assets
• Ionis Pharmaceuticals, Inc.: interest expense
• Ionis Pharmaceuticals, Inc.: current liabilities
• Ionis Pharmaceuticals, Inc.: current accounts payable
• Ionis Pharmaceuticals, Inc.: common-stock repurchase payments
• Ionis Pharmaceuticals, Inc.: operating expenses
• Ionis Pharmaceuticals, Inc.: net inventory
• Ionis Pharmaceuticals, Inc.: selling, general and administrative expense
• Ionis Pharmaceuticals, Inc.: research and development expense

Inspect the source

Entity

Ionis Pharmaceuticals, Inc. / CIK 0000874015

Captured

2026-09-19T11:15:03.040Z

SEC response SHA-256

1156fe0cb26dcc7b40e41723fe2685b758c89b1d56f81659b360ba07b6e6544c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000874015.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))